How should acute viral hepatitis be evaluated and managed?

Evaluation and Management of Acute Viral Hepatitis

Initiate immediate treatment with direct-acting antivirals (DAAs) for acute hepatitis C upon diagnosis without waiting for spontaneous clearance, provide supportive care only for hepatitis A and uncomplicated hepatitis B, and monitor all patients closely for acute liver failure. 1

Initial Diagnostic Evaluation

Obtain comprehensive laboratory testing immediately:

• HCV antibody and HCV RNA when acute hepatitis C is suspected based on exposure history, clinical presentation, or elevated aminotransferases 1
• Complete hepatic function panel including ALT, AST, bilirubin, albumin, and INR to assess synthetic liver function and detect coagulopathy 2
• Complete blood count to identify cytopenias suggesting portal hypertension 2
• Viral hepatitis serologies (HAV IgM, HBsAg, anti-HBc IgM, HCV antibody/RNA) to identify the specific viral etiology 2
• Prothrombin time/INR is critical—if INR ≥1.5 with any mental status change, this defines acute liver failure requiring immediate ICU admission 2

Rule out alternative or coexisting causes: Test for other hepatotropic viruses (hepatitis D if HBV positive, hepatitis E in appropriate clinical scenarios), autoimmune hepatitis markers, and obtain detailed medication/supplement history including all non-prescription products 1, 2

Virus-Specific Management

Acute Hepatitis C: Treat Immediately

The 2020 AASLD-IDSA guidelines represent a major paradigm shift from the 2015 recommendations. The newer guidance prioritizes immediate treatment over observation, based on real-world data showing reduced transmission and prevention of loss to follow-up. 1

• Initiate DAA therapy immediately upon diagnosis of acute HCV with detectable RNA—do not wait for spontaneous clearance 1
• Use the same pangenotypic DAA regimens recommended for chronic HCV infection (no abbreviated courses are currently recommended due to insufficient data) 1
• Monitor hepatic panels (ALT, AST, bilirubin, INR) every 2-4 weeks until resolution 1

Rationale for immediate treatment: Mathematical modeling demonstrates that scaling up DAA treatment reduces HCV incidence and prevalence, especially among high-risk populations (men who have sex with men, people who inject drugs). 1 While 20-50% of acute HCV infections spontaneously clear (usually within 6 months), waiting introduces risk of transmission and patient loss to follow-up. 1

Acute Hepatitis A: Supportive Care Only

• Provide rest, hydration, and symptomatic relief for nausea and malaise—no antiviral therapy has proven effective 2, 3
• Most patients recover completely within 2 months, though 10-15% experience relapsing illness during the first 6 months 2
• Hospitalize only if dehydration from persistent vomiting or signs of acute liver failure develop 2

Post-exposure prophylaxis for contacts:

• Administer hepatitis A immune globulin (IG) to unvaccinated close contacts within 14 days of exposure—provides >85% protection 2
• Target household members, co-habitants, sexual partners, and persons with ongoing close personal contact 2

Acute Hepatitis B: Supportive Care (Antivirals Only for Severe Cases)

• Supportive care is standard for uncomplicated acute hepatitis B—do not routinely treat with antivirals as this may impair natural immunity 2, 3
• Initiate oral nucleoside analogs (entecavir or tenofovir preferred) only for persistent severe hepatitis or acute liver failure 2

Universal Management Principles for All Acute Viral Hepatitis

Strict Avoidance of Hepatotoxins

• Avoid all hepatotoxic medications, particularly acetaminophen, and mandate complete alcohol abstinence 1, 2, 3
• Discontinue all non-essential medications in the setting of severe hepatitis 2

Transmission Prevention Counseling

For acute hepatitis C specifically:

• Counsel patients to avoid sharing injection equipment 1
• Recommend barrier precautions during sex, even in stable monogamous relationships during the acute phase, because transmission risk of bloodborne infections is higher 1
• Refer patients with injection drug use history to addiction medicine specialists and harm reduction services 1

Monitoring for Acute Liver Failure

This is the most critical aspect of management, as acute liver failure is rare (<1%) but life-threatening. 1

• Monitor hepatic panels (ALT, AST, bilirubin, INR) every 2-4 weeks until resolution 1, 2
• Watch specifically for increasing bilirubin and prolonged INR—these signal potential progression to acute liver failure 1, 2
• Immediately refer to a liver transplant center if INR >1.5 with any signs of hepatic encephalopathy 1, 2
• Transfer patients with coagulopathy (INR ≥1.5) and any mental status alteration to ICU immediately—this defines acute liver failure 2

Hospitalization Criteria

Admit patients who develop:

• Persistent vomiting causing dehydration and inability to maintain oral intake 2, 4
• Any alteration in mental status suggesting evolving fulminant hepatic failure 4
• INR >1.5 1
• Signs of acute liver failure (coagulopathy, hepatic encephalopathy, rising bilirubin) 1, 2

Critical Pitfalls to Avoid

• Do not delay ICU transfer for patients with coagulopathy (INR ≥1.5) and mental status changes—this is acute liver failure requiring immediate intensive care 2
• Do not wait for spontaneous clearance in acute hepatitis C—the 2020 guidelines explicitly recommend immediate treatment, reversing the 2015 "watch and wait" approach 1
• Do not use acetaminophen or allow alcohol consumption during acute hepatitis—these are hepatotoxic and can precipitate acute liver failure 1, 2
• Do not routinely treat uncomplicated acute hepatitis B with antivirals—this may impair development of natural immunity 2
• Do not use benzodiazepines for sedation in patients with liver failure 2
• Do not delay early contact with liver transplant services for patients with acute liver failure—transplantation may be the only lifesaving option 2